Efavirenz pharmacokinetics in cerebrospinal fluid and plasma over a 24-hour dosing interval
- PMID: 22687515
- PMCID: PMC3421893
- DOI: 10.1128/AAC.06311-11
Efavirenz pharmacokinetics in cerebrospinal fluid and plasma over a 24-hour dosing interval
Abstract
We determined the pharmacokinetics of efavirenz in plasma and cerebrospinal fluid (CSF) over a 24-h dosing interval in a patient who had undergone a lumbar drain because of cryptococcal meningitis. Drug concentrations were determined by high-performance liquid chromatography-tandem mass spectrometry in paired CSF (n = 24) and plasma (n = 25) samples. The median plasma efavirenz concentration was 3,718 ng/ml (range, 2,439 to 4,952), and the median CSF concentration was 16.3 ng/ml (range, 7.3 to 22.3). The CSF/plasma area-under-the-curve ratio was 0.0044 corresponding to a CSF penetration of 0.44% of plasma.
Figures
Similar articles
-
Protein-free efavirenz concentrations in cerebrospinal fluid and blood plasma are equivalent: applying the law of mass action to predict protein-free drug concentration.Antimicrob Agents Chemother. 2013 Mar;57(3):1409-14. doi: 10.1128/AAC.02329-12. Epub 2013 Jan 7. Antimicrob Agents Chemother. 2013. PMID: 23295919 Free PMC article.
-
Efavirenz concentrations in CSF exceed IC50 for wild-type HIV.J Antimicrob Chemother. 2011 Feb;66(2):354-7. doi: 10.1093/jac/dkq434. Epub 2010 Nov 23. J Antimicrob Chemother. 2011. PMID: 21098541 Free PMC article.
-
In Vivo Profiling and Distribution of Known and Novel Phase I and Phase II Metabolites of Efavirenz in Plasma, Urine, and Cerebrospinal Fluid.Drug Metab Dispos. 2016 Jan;44(1):151-61. doi: 10.1124/dmd.115.065839. Epub 2015 Nov 9. Drug Metab Dispos. 2016. PMID: 26553012
-
Cerebrospinal fluid exposure of efavirenz and its major metabolites when dosed at 400 mg and 600 mg once daily: a randomized controlled trial.Clin Infect Dis. 2015 Apr 1;60(7):1026-32. doi: 10.1093/cid/ciu976. Epub 2014 Dec 11. Clin Infect Dis. 2015. PMID: 25501988 Clinical Trial.
-
Current approach to the acute management of cryptococcal infections.J Infect. 2000 Jul;41(1):18-22. doi: 10.1053/jinf.2000.0696. J Infect. 2000. PMID: 11041709 Review. No abstract available.
Cited by
-
Efavirenz Is Predicted To Accumulate in Brain Tissue: an In Silico, In Vitro, and In Vivo Investigation.Antimicrob Agents Chemother. 2016 Dec 27;61(1):e01841-16. doi: 10.1128/AAC.01841-16. Print 2017 Jan. Antimicrob Agents Chemother. 2016. PMID: 27799216 Free PMC article.
-
Predicting Efavirenz Concentrations in the Brain Tissue of HIV-Infected Individuals and Exploring their Relationship to Neurocognitive Impairment.Clin Transl Sci. 2019 May;12(3):302-311. doi: 10.1111/cts.12620. Epub 2019 Feb 27. Clin Transl Sci. 2019. PMID: 30675981 Free PMC article. Clinical Trial.
-
Treatment of HIV in the CNS: effects of antiretroviral therapy and the promise of non-antiretroviral therapeutics.Curr HIV/AIDS Rep. 2014 Sep;11(3):353-62. doi: 10.1007/s11904-014-0223-y. Curr HIV/AIDS Rep. 2014. PMID: 25063356
-
Nanoformulated Antiretrovirals for Penetration of the Central Nervous System: State of the Art.J Neuroimmune Pharmacol. 2017 Mar;12(1):17-30. doi: 10.1007/s11481-016-9716-3. Epub 2016 Nov 10. J Neuroimmune Pharmacol. 2017. PMID: 27832401 Review.
-
Central nervous system penetration of antiretroviral drugs: pharmacokinetic, pharmacodynamic and pharmacogenomic considerations.Clin Pharmacokinet. 2015 Jun;54(6):581-98. doi: 10.1007/s40262-015-0257-3. Clin Pharmacokinet. 2015. PMID: 25777740
References
-
- Acosta E, et al. 2011. Novel method to assess antiretroviral target trough concentrations using in vitro susceptibility data. 18th Conference on Retroviruses and Opportunistic Infections, Boston, MA
-
- Antinori A, et al. 2005. Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma. Clin. Infect. Dis. 41:1787–1793 - PubMed
-
- Cysique LA, Maruff P, Brew BJ. 2004. Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus-infected/acquired immunodeficiency syndrome (HIV/AIDS) patients across pre- and post-highly active antiretroviral therapy eras: a combined study of two cohorts. J. Neurovirol. 10:350–357 - PubMed
-
- d'Arminio Monforte A, et al. 2004. Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann. Neurol. 55:320–328 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical